Angiogenesis is essential for tumor growth and metastasis. In the process of angiogenesis, the interaction between adhesive proteins of endothelial cells and extracellular matrix components plays an important role by mediating cell attachment, which is indispensable for their motility, and by transmitting the regulatory signals for cell locomotion and proliferation. In this study, we examined the hypothesis that CD44 expressed on the endothelial cell surface is involved in the angiogenesis process. The experiments using calf pulmonary artery endothelial cells (CPAE) and a human microvascular endothelial cell line (HMEC-I) show that a monoclonal antibody against CD44 (clone J 173) inhibits endothelial cell proliferation by about 30% and migration by 25-50%, and abolishes the stimulating effect of hyaluronan polysaccharides on endothelial cell migration and proliferation. This antibody also suppresses the capillary formation of CPAE in an in vitro model of angiogenesis using fibrin matrix. These results provide evidence of the involvement of endothelial-cell-associated CD44 in angiogenesis.o 1996 Wiley-Liss, Inc.Angiogenesis plays a fundamental role in many physiological and pathological processes including wound healing, tissue repair and tumor growth (Folkman, 1995). For the formation of a new vessel, migration of stimulated endothelial cells and subsequent tube formation virtually depend on the occurrence of timely and locally coordinated extracellular proteolysis, cell adhesion and activation during the cell migration. Therefore, the interaction of adhesive proteins expressed on the endothelial cell surface with the components of extracellular matrix is one of the factors determining the occurrence of angiogenesis. Perturbation of these interactions may abolish an ongoing angiogenesis process. For example, blocking the binding of the integrin molecule to matrix-associated vitronectin led to endothelial cell apoptosis and abolished tumor-induced angiogenesis in vivo (Brooks et al., 1994). Furthermore, the interaction of adhesive proteins with their endothelial cell-surface receptors may also activate the process of angiogenesis. For instance, endothelial cells could be stimulated by the surrounding fibrin I1 matrix to form capillary tubes in vitro (Chalupowicz et al., 1995). However, due to the complexity of the mechanisms involved in cell adhesion, the functions of many adhesive molecules on the endothelial cell surface still remain to be determined.One of the examples is CD44, discovered through its role in mediating leukocyte adhesion and lymphocyte homing (Haynes et al., 1989). Although several studies reported the presence of CD44 on endothelial cells such as human microvascular endothelial cells (HMEC-1) (Xu et al., 1994), bovine microvascular endothelial cells (BME) (Bourguignon et al., 1992) and human umbilical endothelial cells (HUVEC) (Liesveld et al., 1994), the role of CD44 expressed on the endothelial cell surface still remains to be clarified. CD44 is a transmembrane molecule with multiple isofo...
The binding of urokinase (u-PA) to its cell surface receptor (u-PAR) is critical for tumor cell invasion. Here, we report that the disruption of this binding by an u-PAR antagonist ATF-HSA inhibits in vitro the motility of endothelial cells in a dose-dependent manner. This inhibition was also observed when the cells were first stimulated with potent angiogenic factors, including bFGF or VEGF.[3H]thymidine incorporation assay demonstrated that ATF-HSA did not affect the cell proliferation. ATF-HSA was more potent than plasmin inhibitors, suggesting that it exerts its effects not solely by inhibiting the remodeling of the extracellular matrix. In fact, analysis of the cell shape change during migration revealed for the first time that its effect is related to a decrease in cell deformability. These results suggest that u-PAR antagonist may be a new approach to control angiogenesis.
Receptor-bound urokinase is likely to be a crucial determinant in both tumor invasion and angiogenesis. We report here that a yeast-derived genetic conjugate between human serum albumin and the 1-135 N-terminal residues of urokinase (u-PA) competitively inhibits the binding of exogenous and endogenous u-PA to its cell-anchored receptor (u-PAR). This hybrid molecule (ATF-HSA) also inhibits in vitro pro-urokinasedependent plasminogen activation in the presence of u-PAR bearing cells. These effects are probably responsible for the observed in vitro inhibition of tumor cell invasion in a reconstituted basement membrane extract (Matrigel).
Summary Our previous studies showed that carboxymethyl benzylamide dextran (CMDB7) blocks basic fibroblast growth factor (FGF-2)-dependent cell proliferation of a human breast epithelial line (HBL1 00), suggesting its potential role as a potent antiangiogenic substance. The derived cell line (HH9), which was transformed with the hst/FGF4 gene, has been shown to be highly proliferative in vitro and to induce angiogenic tumours in nude mice. We show here that CMDB7 inhibits the mitogenic activities of the conditioned media from HBL 100 and HH9 cells in a dose-dependent manner. When HH9 cells were injected s.c. into nude mice, CMDB7 treatment (300 mg kg-' week-') suppressed the tumour take and the tumour growth by about 5Oi/o and 80% respectivety. Immunohistochemical analysis showed a highly significant decrease, by more than threefold, in the endothelial density of viable tumour regions, together with a significant increase in the necrosis area. This antiangiogenic activity of CMDB7 was further demonstrated by direct inhibition of calf pulmonary artery (CPAE) and human umbilical vein (HUVEC) endothelial cell proliferation and migration in vitro. In addition, we showed that CMDB7 inhibits specifically the mitogenic effects of the growth factors that bind to hepann such as FGF-2, FGF-4, platelet-derived growth factor (PDGF-BB) and transforming growth factor (TGF-p1), but not those of epidermal growth factor (EGF) and insulin-like growth factor (IGF-1). These results demonstrate that CMDB7 inhibits FGF-2/FGF-4-dependent tumour growth and angiogenesis, most likety by disrupting the autocrine and paracrine effects of growth factors released from the tumour cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.